Circulating tumour cells in women with advanced oestrogenreceptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive subpopulation after multiple courses of therapy 1,2 . In contrast to HER2-amplified primary breast cancer, which is highly sensitive to HER2-targeted therapy, the clinical significance of acquired HER2 heterogeneity during the evolution of metastatic breast cancer is unknown. Here we analyse circulating tumour cells from 19 women with ER + /HER2 − primary tumours, 84% of whom had acquired circulating tumour cells expressing HER2. Cultured circulating tumour cells maintain discrete HER2 + and HER2 − subpopulations: HER2 + circulating tumour cells are more proliferative but not addicted to HER2, consistent with activation of multiple signalling pathways; HER2 − circulating tumour cells show activation of Notch and DNA damage pathways, exhibiting resistance to cytotoxic chemotherapy, but sensitivity to Notch inhibition. HER2 + and HER2 − circulating tumour cells interconvert spontaneously, with cells of one phenotype producing daughters of the opposite within four cell doublings. Although HER2 + and HER2 − circulating tumour cells have comparable tumour initiating potential, differential proliferation favours the HER2 + state, while oxidative stress or cytotoxic chemotherapy enhances transition to the HER2 − phenotype. Simultaneous treatment with paclitaxel and Notch inhibitors achieves sustained suppression of tumorigenesis in orthotopic circulating tumour cell-derived tumour models. Together, these results point to distinct yet interconverting phenotypes within patient-derived circulating tumour cells, contributing to progression of breast cancer and acquisition of drug resistance.
of patient-matched metastatic tumour biopsies showed increased HER2 + staining, compared with primary tumours (Fig. 1c ). Unlike HER2-amplified breast cancer, HER2 + tumour cells within metastatic lesions did not have evidence of gene amplification (Extended Data Fig. 1d ).
The CTC-iChip efficiently captures viable CTCs 3 , enabling derivation of CTC cultures 4 . We established CTC lines (Brx-42, Brx-82, Brx-142) with discrete HER2 + /HER2 − subpopulations comparable to patient-matched primary CTCs (Fig. 1a, d and Extended Data Fig. 1e , f). Acquired HER2 expression was not due to gene amplification, and no distinguishing mutations were identified between HER2 + and HER2 − subpopulations (Extended Data Fig. 1g and Supplementary  Table 2 ). Fluorescence-activated cell sorting (FACS) of HER2 + versus HER2 − subpopulations showed distinct functional properties: HER2 + CTCs had a higher proliferation rate (Fig. 1e) , with increased staining for the proliferation marker Ki67, but no change in apoptotic markers cleaved-caspase 3 or annexin 5 (Extended Data Fig. 2a, b) .
We tested the relative tumorigenicity of HER2 + versus HER2 − CTCs following injection into the mouse mammary fat pad. Both FACSpurified HER2 + and HER2 − CTCs generated tumours, with HER2 + tumours being larger and having a higher frequency of lung metastases ( Fig. 1f and Extended Data Fig. 2c, d ). Despite differences in proliferation, limiting dilution studies showed that HER2 + and HER2 − CTCs initiate tumours from as few as 200 cells, pointing to comparable progenitor potential (Extended Data Fig. 2e ).
The coexistence of HER2 + and HER2 − CTCs, despite differing proliferation rates, led us to test whether these subpopulations are capable of interconversion. After 4 weeks in culture, FACS-purified green fluorescent protein (GFP)-tagged HER2 − CTCs acquired HER2 + cells (Brx-82: 42%; Brx-142: 46%), while HER2 + CTCs generated HER2 − cells at lower efficiency (Brx-82: 5%; Brx-142: 11%) ( Fig. 2a, b and Extended Data Fig. 3a ). By 8 weeks, the parental HER2 + /HER2 − composition was nearly re-established ( Fig. 2b) . This interconversion was also evident by mixing equal proportions of GFP + /HER2 + and GFP − / HER2 − CTCs, with the emergence of GFP + /HER2 − and GFP − /HER2 + cells, respectively (Extended Data Fig. 3a ).
To better define the timing of HER2 + /HER2 − interconversion, we established single-cell-derived CTC colonies using HER2-based FACS, followed by sequential confocal microscopy. Colonies were scored for HER2 and EpCAM expression at 1-, 3-, 5-to 9-, 10-to 19-and > 20-cell stages. Single HER2 − CTCs initially proliferated slowly (Extended Data Fig. 3b ), and first acquired HER2 + daughter cells at the 5-to 9-cell stage (6.5%), with rapid interconversion thereafter (10-19 cells: 47%, > 20 cells: 59%; Fig. 2c, d) . The more rapidly proliferating single HER2 + CTCs also generated HER2 − progeny at the 5-to 9-cell stage (5%), but the proportion of HER2 − CTCs rose more slowly (10-19 cells: 17%, > 20 cells: 22%; Fig. 2c, d ). Thus, interconversion between HER2 + /HER2 − phenotypes occurs spontaneously as early as four cell doublings.
Interconversion between HER2 + and HER2 − phenotypes was also tested in vivo by orthotopic inoculation of FACS-purified cultured CTCs. Tumours established from HER2 − CTCs displayed HER2 + subpopulations, and vice versa ( Fig. 2e and Extended Data Fig. 3c ). In vivo interconversion was confirmed by injecting a 1:1 mixture of GFP + /HER2 + and GFP − /HER2 − CTCs (or the converse), followed by dual GFP and HER2 IHC. Within mixed tumours, GFP-tagged HER2 − CTCs produced GFP + /HER2 + cells (44%), and in separate tumours, GFP-tagged HER2 + CTCs generated GFP + /HER2 − cells (21%) ( Fig. 2f and Extended Data Fig. 3d ).
To define the molecular characteristics of HER2 + versus HER2 − CTCs, we quantitatively mapped the global proteomes (> 6,300 proteins) of FACS-purified subpopulations (Brx-42, Brx-82, Brx-142) using multiplexed mass spectrometry (MS) with isobaric tandem mass tags (TMT) 5 ( Supplementary Table 3 ). While proteome profiles of individual cell lines were distinct, they shared differences between HER2 + and HER2 − subpopulations (Pearson correlation coefficients: Brx-82 versus Brx-142 = 0.81; Brx-82 versus Brx-42 = 0.71; Brx-42 versus Brx-142 = 0.64) ( Fig. 3a and Extended Data Fig. 4a, b ). HER2 + CTCs showed enrichment (Pathway Interaction Database (PID)) of receptor tyrosine kinase (RTK) and pro-growth signalling (GSEA, false discovery rate (FDR) ≤ 0.25) ( Fig. 3b and Supplementary Tables 3 and 4 ). Phosphotyrosine blots from the HER2 + subpopulations confirmed RTK phosphorylation (HER2, HER3, HER4, insulin receptor (INSR), EPHA1, EPHA2 and EPHA10), which was absent from matched Letter reSeArCH Fig. 4c ). scRNA-seq analysis of 15 primary HER2 + CTCs compared with 7 HER2 − CTCs from matched patient blood samples showed enrichment for 15 of 32 shared pathways (ERBB1, ERBB2/ERBB3, IGF1, EPHA2, MET) identified by MS analysis of cultured CTC lines ( Fig. 3b , Extended Data Fig. 4d , e and Supplementary Tables 4 and 5 ). In contrast to HER2 + CTCs, MS analysis of cultured HER2 − CTCs showed increased expression of proteins enriched in Notch (HES/HEY, Presenilin 1 (PS1)) and DNA damage pathways (AuroraB, ATM, ATR, Fanconi) (GSEA, FDR ≤ 0.25) ( Fig. 3c and Supplementary Tables 3 and 4 ).
To explore the potential therapeutic significance of pathways differentially activated in HER2 + versus HER2 − CTC subpopulations, we screened a panel of 55 drugs selected both for clinical relevance and for the ability to target MS-identified pathways (Supplementary Table 6 ). HER2 + CTCs were no more sensitive to the HER2 inhibitor lapatinib than HER2 − CTCs (half-maximum inhibitory concentration (IC 50 ) = 1 μ M), indicating they were not 'oncogene addicted' to HER2, unlike the HER2-amplified SKBR3 cells (IC 50 = 5 nM) ( Fig. 4a , Extended Data Fig. 5a, b ). However, dual inhibition of HER2 and IGF1R, another RTK activated in HER2 + CTCs, was cytotoxic to HER2 + but not HER2 − CTCs (Fig. 4a ), suggesting inhibition of multiple receptor tyrosine kinases may be effective in treating HER2 + CTCs. Compared with HER2 + CTCs, HER2 − CTCs showed reduced sensitivity to the chemotherapeutic agents docetaxel, doxorubicin and 5-fluorouracil (5-FU) ( Fig. 4b and Extended Data Fig. 5a , c), but increased sensitivity to γ -secretase inhibitors, which suppress Notch activity ( Fig. 4b and Extended Data Fig. 5a, d ). Despite proteomic enrichment for Aurora B signalling, HER2 − CTCs were not differentially sensitive to Aurora family inhibitors ( Fig. 3c , Extended Data Fig. 5a and Supplementary Tables 3 and 4 ).
The increased NOTCH1 in HER2 − CTCs observed by quantitative MS and confirmed by western blot (Extended Data Fig. 6a and Supplementary Tables 3 and 4 ) was inversely correlated with HER2 expression within primary CTCs and CTC lines, shown by scRNA-seq and immunostaining (Extended Data Fig. 6a ). We therefore tested the consequences of suppressing HER2 or activating Notch signalling in HER2 + CTCs.
Manipulation of NOTCH1 or its downstream effector NFE2L2/NRF2 in cultured HER2 + CTCs did not reduce HER2 expression (Extended Data Fig. 6b ). However, inhibition of HER2 using lapatinib or short interfering RNA (siRNA) led to increased expression of NOTCH1, its ligands JAG1 and DLL1, and Notch-regulated genes HES1, HEY1 and HEY2 ( Fig. 4c and Extended Data Fig. 6c ), confirming previous reports from HER2-amplified breast cancer cells 6, 7 (Extended Data Fig. 6c ). Suppression of HER2 also resulted in increased expression of genes (GCLC, GGT1, GPX1, GPX4, HMOX1) downstream of Notch-regulated NRF2, a transcriptional regulator of anti-oxidant/glutathione metabolism pathways 8, 9 (Extended Data Fig. 6d ). Thus, expression of HER2 in CTCs appears to mediate downregulation of the NOTCH1/NRF2 axis, potentially switching between proliferative and survival-prone phenotypes.
In addition to suppressing HER2 directly, we tested additional stimuli capable of modulating the HER2 + /HER2 − interconversion. Treatment of HER2 + CTCs with low doses of docetaxel (1 nM) or induction of oxidative stress with hydrogen peroxide (H 2 O 2 ; 10 mM) induced rapid shifts from HER2 + to HER2 − (30% conversion, > 70% survival) ( Fig. 4d ). To exclude differential cell death, we demonstrated acceleration in the appearance of HER2 − progeny from FACS-purified single HER2 + CTCs (5-to 9-cell stage: 45%; > 10-cell stage: 62%) ( Fig. 4e and Extended Data Fig. 6e ). Thus, exposure to cytotoxic/oxidative stress mediates a switch to a less proliferative but more drug-resistant phenotype.
To model the potential significance of HER2 + /HER2 − interconversion in vivo, we generated orthotopic mammary xenografts from FACS-purified subpopulations and analysed tumours before and after treatment with paclitaxel. Purified HER2 + CTCs generated mixed tumours (88% HER2 + , 12% HER2 − ) and showed dramatic tumour shrinkage following paclitaxel treatment. The recurrent tumour showed a transient reduction in HER2 + with a corresponding increase in HER2 − composition following chemotherapy (2 weeks: 39% HER2 + ; 7 weeks: 74% HER2 + ; Fig. 4f ). Purified HER2 − CTCs also gave rise to a mixed tumour (35% HER2 + , 65% HER2 − ), but paclitaxel induced only a limited delay in tumour growth with a minimal effect on HER2 content. Shedding of CTCs was also suppressed by paclitaxel in HER2 + but not HER2 − tumours (Extended Data Fig. 6f ). The chemotherapyinduced shift in HER2 composition was also evident following inoculation of parental CTC cultures (untreated 65% HER2 + ; post-therapy 30% HER2 + ; Extended Data Fig. 6g ). Finally, we generated tumours from a 1:1 mixture of GFP-tagged HER2 + and untagged HER2 − cells, demonstrating a shift from GFP + /HER2 + to GFP + /HER2 − cells following paclitaxel treatment (untreated: 70% GFP + /HER2 + , post-therapy: 42% GFP + /HER2 + ; Extended Data Fig. 6h ). The potent effect of chemotherapy on HER2 + /HER2 − phenotypes in vivo may reflect both reduced drug-sensitivity of HER2 − cells, as well as stress-induced HER2 + to HER2 − switching.
Given the demonstrated susceptibility of HER2 − CTCs to Notch inhibitors, we combined paclitaxel with either of two γ -secretase Table 3 ). b, c, Cytoscape network maps (top) and GSEA pathway analysis (bottom) depicting proteins enriched by greater than log 2 (0.5) by quantitative MS in (b) HER2 + and (c) HER2 − CTCs (GSEA FDR ≤ 0.25; nominal P cut-off < 0.05; Supplementary Table 4 ). Coloured shapes represent proteins within denoted pathways. Red asterisks highlight RTK pathways in b, and Notch pathways in c.
inhibitors (LY-411575; RO4929097) in treating mice with tumours initiated from parental CTC lines. Compared with paclitaxel alone, the combination therapy significantly delayed onset of tumour recurrence, while Notch inhibition alone had no effect on tumour growth ( Fig. 4g and Extended Data Fig. 6i ).
Taken together, we have used primary and cultured CTCs from patients with ER + /HER2 − breast cancer who developed metastatic multidrug-resistant disease to show that coexisting distinct HER2 + and HER2 − tumour cell subpopulations may interconvert, with striking consequences for disease progression and drug response. The comparable tumour initiating potential and similar expression of stem cell marker ALDH1 in HER2 + and HER2 − CTCs suggest underlying tumour cell plasticity in these advanced patient-derived breast CTC lines, rather than a hierarchical cancer stem-cell model as described in drug-resistant subpopulations within established breast cancer cell lines 7,10-15 . While expression of NOTCH1 and other embryonic markers has been reported in rare, quiescent cells within primary breast tumours 7,16-18 , the NOTCH1 + CTCs reported here constitute a major cell population, exhibiting both persistent cell proliferation in vitro and tumorigenesis in vivo. Thus, we propose a dynamic model, in which the equilibrium between HER2 + and HER2 − cells within a heterogeneous tumour population is driven by spontaneous interconversion between these phenotypes, with the more rapidly proliferating HER2 + cells prevalent under baseline conditions, and environmental or therapy-induced stress enhancing conversion to the more resistant HER2 − phenotype. Neither molecular profiling nor functional studies have revealed secreted factors that affect the mutual survival of HER2 + and HER2 − CTCs, but we cannot exclude such additional factors.
Finally, the properties of patient-derived CTC lines established after multiple courses of therapy provide relevant insight to the treatment of drug-refractory, advanced breast cancer. While clinical trials are evaluating the efficacy of HER2-targeted therapy in HER2 − breast cancer with acquired HER2 + CTCs 1,19-21 , our observations indicate that acquisition of HER2 does not indicate HER2 oncogene dependence and drug susceptibility; instead it constitutes a marker of a proliferative, multi-RTK state. Furthermore, the interconversion of chemotherapysensitive HER2 + /NOTCH1 − and NOTCH inhibitor-sensitive HER2 − / NOTCH1 + CTCs suggests that dual treatment, as modelled here, may be required for effective treatment. Clinical trials so far have had limited success sequentially administering embryonic pathway inhibitors targeting Hedgehog, Wnt or Notch to inhibit cancer stem cells following initial chemotherapy 16, [22] [23] [24] [25] . The rapid interconversion between proliferative and drug-resistant CTC subpopulations raises the possibility that simultaneous combination therapy may provide a novel strategy for clinical validation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Determination of reads-per-million (RPM). Trimmomatic was used to crop reads lengths to 50 nucleotides, and to remove the TruSeq3-PE-2 Illumina adapters. The paired-end reads were then aligned using tophat2 and bowtie1 with the no-noveljuncs argument set with human genome version hg19 and transcriptome defined by the hg19 genes.gtf table from http://genome.ucsc.edu. Reads that did not align or aligned to multiple locations were discarded. The number of reads aligning to each gene was then determined using htseq-count. Samples that had fewer than 10 5 reads were discarded. The read count for each gene was divided by the total counts assigned to all genes and multiplied by one million to form the reads per million (RPM). Samples for which the expression of the white blood cell marker PTPRC (CD45) was greater than 10 RPM were discarded. Single-cell RNA-seq data have been deposited in the Gene Expression Omnibus under accession number GSE75367. Bimodality. To establish that the distribution of HER2 expression in CTCs is multi-modal, we applied the Hartigans' dip test as implemented in the diptest R-package to the log 10 (RPM + 1) values with 10 RPM as the threshold to define HER2 − versus HER2 + CTCs. To establish that the distribution has two modes and not more, we applied the density function of R with default values to the log 10 (RPM + 1) values. Gene set enrichment analysis of RNA-seq and quantitative proteomics data. On the basis of the analysis of bimodality above, we defined HER2 + samples to be those for which the expression of HER2 exceeded 10 RPM and defined the rest to be HER2 − . For the mass spectrometric data, enrichment of signalling pathways was determined by submitting the average log 2 fold-change in protein abundance between the HER2-high and HER2-low samples to the pre-ranked function of the Broad Institute's GSEA software using gene sets in the Pathway Interaction Database (PID) and KEGG as curated in version 4 of the Broad Institute's MSigDB (http://www.broadinstitute.org/gsea/msigdb/). Pathway enrichment for the RNAseq of the CTCs was done the same way with the exception that the full RPM matrix for the CTCs and the HER2 + versus HER2 − distinction was input to the GSEA software instead of log 2 fold-change. Quantitative proteomics. CTC cell pellets were re-suspended in lysis buffer containing 75 mM NaCl, 50 mM HEPES (pH 8.5), 10 mM sodium pyrophosphate, 10 mM NaF, 10 mM β -glycerophosphate, 10 mM sodium orthovanadate, 10 mM phenylmethanesulfonylfluoride, Roche Complete Protease Inhibitor EDTA-free tablets and 3% sodium dodecyl sulfate. Cells were lysed by passing them ten times through a 21-gauge needle, and the lyses were prepared for analysis on the mass spectrometer essentially as described previously 5 . Briefly, reduction and thiol alkylation were followed by purifying the proteins using MeOH/CHCl3 precipitation. Protein digest was performed with Lys-C and trypsin, and peptides were labelled with TMT-10plex reagents (Thermo Scientific) 33 and fractionated by basic pH reversed phase chromatography. Multiplexed quantitative proteomics was performed on an Orbitrap Fusion mass spectrometer (Thermo Scientific) using a simultaneous precursor selection (SPS)-based MS3 method 34 . MS2 spectra were assigned using a SEQUEST-based proteomics analysis platform 35 . On the basis of the target-decoy database search strategy 36 and employing linear discriminant analysis and posterior error histogram sorting, peptide and protein assignments were filtered to a FDR of < 1% (ref. 35) . Peptides with sequences that were contained in more than one protein sequence from the UniProt database were assigned to the protein with most matching peptides 35 . TMT reporter ion intensities were extracted as that of the most intense ion within a 0.03-thomson window around the predicted reporter ion intensities in the collected MS3 spectra. Only MS3 with an average signal-to-noise value larger than 40 per reporter ion as well as with an isolation specificity 5 larger than 0.75 were considered for quantification. A two-step normalization of the protein TMT-intensities was performed by first normalizing the protein intensities over all acquired TMT channels for each protein on the basis of the median average protein intensity calculated for all proteins. To correct for slight mixing errors of the peptide mixture from each sample, a median of the normalized intensities was calculated from all protein intensities in each TMT channel, and protein intensities were normalized to the median value of these median intensities.
Protein interactions were extracted from the String database (high confidence score > 0.7) 37 . Overlapping proteins were assigned to the pathway with the greatest number of proteins, and enriched PID pathways were ranked by log 10 (P value) to the nearest thousandth. Mass spectrometry raw data have been deposited in the MassIVE proteomics data repository under the accession number MSV000079419. Drug screens. Drugs were obtained from the MGH Center for Molecular Therapeutics and are listed in Supplementary Table 6 . They were chosen because of their common clinical use for treatment of breast cancer or unique targeting of epigenetic/stem cell pathways. One thousand cells were seeded in tumour sphere media in 384-well ultra-low attachment plates in triplicate wells on duplicate plates 24 h before the addition of drugs. Three independent drug concentrations centred on the reported IC 50 were used (Supplementary Table 6 ). Cell viability was assayed 6 days after drug treatment with CellTiter-Glo (Promega) and was normalized to corresponding untreated controls 38 . Mouse xenograft assays and drug treatment. In compliance with ethical regulations and approved by the animal protocol (IACUC 2010N000006), 6-week-old female NSG (NOD. Cg-Prkscsdid Il2rgtm1Wjl/SzJ) mice from Jackson Laboratories were anaesthetized with isofluorane, and GFP-LUC labelled CTCs (200,000, 20,000 and/or limiting dilutions as low as 200 cells) or 50:50 mixed CTCs (GFP-LUC + /HER2 + : Untagged/HER2 − , and the converse) were injected into the fourth right mammary fat pad. A 90-day release 0.72 mg oestrogen pellet (Innovative Research of America) was implanted subcutaneously behind the neck of each mouse. Tumour growth was monitored weekly by in vivo imaging using IVIS Lumina II (PerkinElmer) following intraperitoneal injection (150 μ l per animal) of d-luciferin substrate (Sigma). For in vivo drug sensitivity testing, Paclitaxel (10 mg/kg) was administered weekly by intravenous injection for 4 consecutive weeks. Notch inhibitors (Notchi 2 ) LY-411575 (10 mg/kg) or (Notchi 3 ) RO429097 (10 mg/kg) were administered daily (5 days on/2 days off) via oral gavage in 2% solvent (2% sodium caroboxymethyl cellulose) for 4 consecutive weeks. No animal randomization or blinding was used for these mouse studies. All animal studies used six to eight mice per condition to ensure sufficient statistical power.
Extended Data Figure 3 | Dynamics of HER2 + and HER2 − interconversion. a, FACS-purified HER2 + and HER2 − subpopulations from CTC line Brx-82 were monitored over 28 days to determine shifts in the composition of sorted populations. Representative data of two independent experiments are shown. b, Growth curves for HER2 + (red) and HER2 − (blue) FACS-purified single cell clones from CTC line Brx-142; two-way ANOVA, P < 0.0001; n = 20. c, IHC HER2 staining of tumour xenografts derived from unlabelled HER2 − and HER2 + CTCs showing acquisition/loss of HER2 (brown), respectively. Arrows indicate regions of HER2 acquisition/loss. Representative image from at least five independent fields; n = 8. ER + /HER2 − and HER2-amplified breast cancers are shown below as controls. d, Low-magnification (landscape) view of HER2 IHC staining of tumour xenografts derived from mixed HER2 + and HER2 − CTC cultures containing either GFP-tagged HER2 + /HER2 − cells (high magnification images are shown in Fig. 2f ). Top: representative GFPtagged HER2 − cells give rise to GFP + /HER2 + cells (GFP: cytoplasmic red stain, HER2: cell surface brown stain). Bottom: GFP-tagged HER2 + cells produce GFP + /HER2 − cells. Scale bar, 100 μ m.
